Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

Mar 04, 2024 8:30 am EST

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024

Feb 27, 2024 8:00 am EST

Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop

Feb 26, 2024 8:00 am EST

Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer

Feb 15, 2024 8:00 am EST

IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan

Jan 30, 2024 8:00 am EST

U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer

Jan 29, 2024 8:00 am EST

IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class

Jan 16, 2024 8:00 am EST

IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation

Jan 12, 2024 4:05 pm EST

IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Jan 10, 2024 8:00 am EST

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results

Jan 03, 2024 8:00 am EST

New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2025 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023